Trial | NCT04312347  Report issue

Title

Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels
Tamoxifen Dose Adjustment on ER+ Breast Cancer Patients Based on Genomic and Metabolite Concentrations Analysis

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    151
The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.
Study Started
Sep 06
2019
Primary Completion
May 01
2021
Study Completion
Jun 30
2021
Last Update
Aug 05
2021

Drug Tamoxifen dose adjustment

Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.

Personalized dosing of tamoxifen Experimental

Increase tamoxifen dose into 40 mg/day for patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype.

Criteria 

Inclusion Criteria:

Diagnosed with ER+ breast cancer
Have taken tamoxifen daily for at least 2 months

Exclusion Criteria:

Have not taken tamoxifen daily for at least 2 months
No Results Posted